Chronic fatigue

Alyve Wellness Unveils its AI-enabled Personalised Vitamin Solution

Retrieved on: 
Friday, December 23, 2022
Pharmacy, Chronic fatigue, AI, Sleep, Vitamin, Exercise, Intellectual property, Nutritionist, ADD, Dietary supplement, Online shopping

The online consultation's AI backend is based on decision algorithm nodes that ensure the best recommendations for each user are presented.

Key Points: 
  • The online consultation's AI backend is based on decision algorithm nodes that ensure the best recommendations for each user are presented.
  • The AI platform is flexible enough to accommodate input data from people with a range of age groups, lifestyles and needs, ensuring that almost anyone can benefit from a personalised solution.
  • Sam Price, founder of Alyve Wellness said: "I was driven to start Alyve after suffering from chronic fatigue and being diagnosed with ADD.
  • Two years and two funding rounds later, over 20,000 customers reminds us just how important - and achievable - personalised wellbeing is in the age of AI.

Cerulean Human Health Performance Welcomes Dr. Jamie Wright as Its New Medical Director

Retrieved on: 
Monday, October 24, 2022
OB, Weight loss, Nutritional science, Chronic fatigue, Therapy, Autoimmune disease, Stroke, Immunity, HBOT, Medicine, Patient, Brain, Private practice, Inflammation, Center, Lyme disease, Health, Pain, Master's degree, Metabolism, GLOBE, Master, Medical device, Cerulean

In 2012, Dr. Wright sold his OB/GYN practice to start building The Centers for Balanced Living, a micro-clinics business focused on age management and health optimization.

Key Points: 
  • In 2012, Dr. Wright sold his OB/GYN practice to start building The Centers for Balanced Living, a micro-clinics business focused on age management and health optimization.
  • After moving to Arizona in 2018, Dr. Wright began working with CERULEAN Human Health Performance as a medical consultant, providing medical and operational guidance to Cerulean's team.
  • - Alicia Fortune, Clinic Director
    CERULEAN Human Health Performance opened its doors in the fall of 2015, as one of the first cellular level Precision Health and Performance centers in Arizona.
  • CERULEAN comprehensive approach of Lifestyle Cellular Health Therapeutics is centered around Hyperbaric Oxygen Therapy (HBOT) combined with other complementary rejuvenative modalities.

Dynamic Neural Retraining System Offers Drug-Free Solution for Patients Suffering from Long COVID and Other Complex Health Conditions

Retrieved on: 
Tuesday, September 27, 2022
Infectious Diseases, Health, Neurology, Nervous system, Toxicity, Health, Inflammation, Memory, COVID-19, Brain, MD, Conditional sentence, Fibromyalgia, Learning, COVID, Program, Patient, Trauma, CEO, Chronic Lyme disease, Mold, Chronic fatigue, Limbic system, Lyme disease, Health insurance

The Dynamic Neural Retraining System (DNRS), a leader in neural rehabilitation, today announced the launch of DNRS 2.0, a drug-free, self-directed method for helping patients manage a growing list of chronic and hard-to-treat conditions, including lingering effects of COVID-19 (long COVID).

Key Points: 
  • The Dynamic Neural Retraining System (DNRS), a leader in neural rehabilitation, today announced the launch of DNRS 2.0, a drug-free, self-directed method for helping patients manage a growing list of chronic and hard-to-treat conditions, including lingering effects of COVID-19 (long COVID).
  • The program uses the principles of neuroplasticity to regulate the autonomic nervous system function and reverse limbic system impairment.
  • DNRS provides participants with an easy-to-follow, step-by-step program, which integrates components of behavioral therapy, mindfulness-based desensitization techniques, neuro-linguistic programming, and more.
  • Dynamic Neural Retraining System is a drug-free, self-directed neural rehabilitation program, which uses the principles of neuroplasticity to regulate autonomic nervous system function and reverse limbic system impairment.

Vivos Announces 4th Annual Breathing Wellness Conference in Cancún, Mexico, With Full Slate of World-Renowned Speakers

Retrieved on: 
Tuesday, August 23, 2022
Security (finance), Degenerative disease, CEO, Technology, U.S. Securities and Exchange Commission, Securities Exchange Act of 1934, Program, Securities Act of 1933, DDS, Friends, Therapy, NASDAQ, Sydney Hilton Hotel bombing, Obstructive sleep apnea, Dentist, Tissue, Risk, SEC, Investment, Type 2 diabetes, Chronic fatigue, GLOBE, Conference, Company, OSA, Dementia, Snoring, VIP, Industry, CARE, Patient, Apnea–hypopnea index, Pharmaceutical industry, Dentistry, Vivos

The conference will be hosted by The Vivos Institute, the educational branch of Vivos Therapeutics.

Key Points: 
  • The conference will be hosted by The Vivos Institute, the educational branch of Vivos Therapeutics.
  • "I have met some of my closest friends and some of the most inspirational dentists at this conference.
  • "I invested to bring 12 team members across the country for the Vivos Breathing Wellness Conference last year," said Dr. James Massa, owner of Massa Dental Center in Naples, Florida, and a Vivos Integrated Provider.
  • The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using The Vivos Method.

AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID

Retrieved on: 
Thursday, July 28, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Erasmus MC, Long COVID, CFS, Brain, Time, Nursing, Lists of diseases, PASC, Inspectorate, Food, Chronic fatigue syndrome, Pancreatic cancer, Research, Poly, AIM, Fatigue, Private Securities Litigation Reform Act, Degenerative disease, Family, Immune system, Access, Exercise, FDA, Company, Cancer, Patient, COVID, PSLRA, Post-exertional malaise, Therapy, Chronic fatigue, IND, Pharmaceutical industry, COVID-19, Rintatolimod

We remain committed to advancing development of Ampligen as a therapeutic for the treatment of Long COVID or Post-Acute Sequelae of Covid (PASC) and look forward to further evaluating its potential.

Key Points: 
  • We remain committed to advancing development of Ampligen as a therapeutic for the treatment of Long COVID or Post-Acute Sequelae of Covid (PASC) and look forward to further evaluating its potential.
  • Based in part on these early positive data, AIM is continuing to work toward filing an IND application with the FDA for a Phase 2 study of Ampligen for the treatment of Post-COVID conditions.
  • The first subject fulfilled the current criteria for long COVID disease and had no contraindications.
  • Significant additional testing and trials will be required to determine whether Ampligen will be an effective treatment for Long COVID.

Renowned Health Strategist Haylie Pomroy Named Assistant Director of Integrative Medicine at Nova Southeastern University

Retrieved on: 
Wednesday, July 13, 2022
Disease, College of Osteopathic Medicine of the Pacific, The New York Times, Goal, Philosophy, Chronic fatigue, Functional medicine, Metabolism, Homeopathy, College, Nova Southeastern University, Autoimmunity, Education, Animal, Burn, Science, Degenerative disease, Rebecca Pomroy, Chronic fatigue syndrome, Wellness, Human body, Micronutrient, CEO, Plant, Alternative, Herbal medicine, Medicine, COVID-19, Physician, Prescription, Founder, Digestion, Assistant, Health, Cooking, Alternative medicine, Biochemistry, Osteopathic medicine in the United States, Disorder, Microdeletion syndrome, Research, Soil, Hospital, National Center for Complementary and Integrative Health, Curriculum, Colorado State University, University, Doctor of Philosophy, Kumasi Centre for Collaborative Research, Institute, Veterinary medicine, Dietary supplement, Food

MIAMI, July 13, 2022 /PRNewswire/ -- The Haylie Pomroy Group announces today that Founder and CEO, Haylie Pomroy, has been named Assistant Director of Integrative Medicine at the Dr. Kiran C. Patel College of Osteopathic Medicine Center (College of Osteopathic Medicine) and the Institute for Neuro-Immune Medicine (INIM) at Nova Southeastern University.

Key Points: 
  • Pomroy to expand the integrative medicine clinics at the Dr. Kiran C. Patel College of Osteopathic Medicine Center for Collaborative Research and Institute for Neuro-Immune Medicine
    MIAMI, July 13, 2022 /PRNewswire/ -- The Haylie Pomroy Group announces today that Founder and CEO, Haylie Pomroy, has been named Assistant Director of Integrative Medicine at the Dr. Kiran C. Patel College of Osteopathic Medicine Center (College of Osteopathic Medicine) and the Institute for Neuro-Immune Medicine (INIM) at Nova Southeastern University .
  • In this role, Pomroy will expand the Integrative Medicine clinics at both the College of Osteopathic Medicine and INIM.
  • "We are so excited to welcome Haylie Pomroy to Nova Southeastern University, and we enthusiastically welcome her medical expertise in and passion for Integrative Medicine," says Nancy Klimas, Director of The Institute for Neuro-Immune Medicine at Nova Southeastern University.
  • In addition to The Haylie Pomroy Group , which has helped millions of people lose unwanted pounds and gain immeasurable strength and energy, Haylie is also the Assistant Director of Integrative Medicine at the Dr. Kiran C. Patel College of Osteopathic Medicine Center for Collaborative Research and Institute for Neuro-Immune Medicine at Nova Southeastern University.

1 in 50 Women Will Suffer From Parathyroid Disease

Retrieved on: 
Wednesday, July 6, 2022
People, Well, Kidney failure, Diagnosis, Surgeon, View, Patient, Arrhythmia, Heart, Hyperparathyroidism, Research, University, Tissue, Brain, Parathyroid gland, Anatomy, Chronic fatigue, Element, Blood, Disease, Mark (given name), Neck, Depression, Gastrointestinal tract, Calcium, Endocrine system, Human body, Kidney, Woman, Risk, Cancer, Parathyroid disease, Neoplasm, Exocrine gland, Parathyroid hormone, Busch Gardens, Human, Mammal, Hospital, Headache, Hypertension, Osteoporosis, Amnesia, PTH, Bone pain, Muscle, Eating, Multimedia, Medical imaging, Phosphorus, Pharmaceutical industry, Dentistry, EU

Hyperparathyroidism (parathyroid disease) is the most common condition of parathyroid glands, caused by the development of a tumor on one or more parathyroid glands.

Key Points: 
  • Hyperparathyroidism (parathyroid disease) is the most common condition of parathyroid glands, caused by the development of a tumor on one or more parathyroid glands.
  • In fact, the Norman Parathyroid Center cites that 1 in 50 women will suffer from parathyroid disease at some point in their lives.
  • The surgeons at the Norman Parathyroid Center are by far the most experienced parathyroid surgeons in the world performing 70+ parathyroid operations per week.
  • Located in Tampa, Florida, the Norman Parathyroid Center is the leading parathyroid gland tumor treatment center in the world, performing nearly 3,800 parathyroid operations annually.

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium

Retrieved on: 
Friday, June 10, 2022
Biomarker, Company, Government budget balance, Plasma, Inflammation, Pain, Â, Citrulline, Food and Drug Administration, CGMP, Clinical research, Disorder, Șaeș, PMD, SGC, Food, Pharming, Pharmacokinetics, Ageing, Alzheimer's disease, Trial of the century, Social isolation, Quality of life, Life expectancy, CNS, Nitric oxide, CYCN, AES, Cognition, Clinical trial, CIAS, RNA transfection, Guanylate cyclase, Cerebrospinal fluid, Patient, Chronic fatigue, Muscle weakness, Mutation, Cognitive deficit, PK, CSF, Research, Physiology, Mitochondrial encephalomyopathy, UMDF, LinkedIn, Disease, ADV, Nasdaq, Skeletal muscle, Pharmacology, NO, Therapy, GLOBE, PGIC, Twitter, Mitochondrial disease, Safety, Medical imaging, Dietary supplement, Pharmaceutical industry, Schizophrenia, MELAS

CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced positive topline data in its signal-seeking clinical study of CY6463, for the potential treatment of Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS). Chad Glasser, Pharm.D., Director of Clinical Research at Cyclerion Therapeutics, will present results from this clinical study today during the Clinical Trial Updates Panel at the United Mitochondrial Disease Foundation (UMDF) Mitochondrial Medicine 2022 Symposium, taking place June 8-11, 2022, in Phoenix, Arizona.

Key Points: 
  • Chad Glasser, Pharm.D., Director of Clinical Research at Cyclerion Therapeutics, will present results from this clinical study today during the Clinical Trial Updates Panel at the United Mitochondrial Disease Foundation (UMDF) Mitochondrial Medicine 2022 Symposium , taking place June 8-11, 2022, in Phoenix, Arizona.
  • The positive data from this study further support the potential of CY6463, the first and only CNS-penetrant sGC stimulator in clinical development, to provide therapeutic benefit to people living with MELAS.
  • We are excited by the strength of these data and consistency across disease domains, which support the further advancement of CY6463 as a potential treatment option.
  • A video presentation of the topline data is available on the Investor page of the Cyclerion website.

Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b “FORTRESS” Clinical Trial for Fibromyalgia

Retrieved on: 
Thursday, April 28, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, Clinical Trials, Functional somatic syndrome, DNA, CEO, Famciclovir, Time, Fatigue, Simplex, Fibromyalgia, Patient, Nasdaq, Myalgia, FDA, Chronic fatigue syndrome, Pain, Valaciclovir, Therapy, FM, Anxiety, Short bowel syndrome, COVID-19, Food, Celecoxib, Sleep, Company, Conditional sentence, Diagnosis, US, PASC, Center, Ageing, Depression, Chronic fatigue, Physician, BHC, Pain scale, Trial of the century, Enzyme, American College of Rheumatology, Government budget balance, Attention, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American College, Center of excellence, Pharmaceutical industry, Vaccine, Medical imaging

Virios lead antiviral development candidate, orally administered IMC-1, is a novel, proprietary, fixed dose, antiviral therapy combining famciclovir and celecoxib.

Key Points: 
  • Virios lead antiviral development candidate, orally administered IMC-1, is a novel, proprietary, fixed dose, antiviral therapy combining famciclovir and celecoxib.
  • The FORTRESS study builds on the statistically significant results from the Companys previously completed Phase 2a FM clinical study.
  • Virios Therapeutics is conducting FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1).
  • Evidence of IMC-1s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial.

The Korea Society of Ginseng Announces Red Ginseng Reduces Fatigue and Stress

Retrieved on: 
Tuesday, April 26, 2022
Chronic cough, DNA, Lethargy, Woman, COVID-19, WHO, Fatigue, Ageusia, Genetics, Research, Taste, The Korea Society, Molecular medicine, Effect, Department, Patient, Breathe Me, OC43, Conference, Hematology, Learned helplessness, Professor, BFI, Sejong University, Female, Ewha Womans University, Colorectal cancer, Smell, Coronavirus, Anosmia, John Foster Dulles, Male, Chronic fatigue, Cancer, Animal, Hospital, Pharmaceutical industry, Medicine, Dietary supplement

SEOUL, South Korea, April 26, 2022 /PRNewswire/ -- The Korea Society of Ginseng disclosed the results of a study titled The Effect of Red Ginseng on Improving Fatigue, Lethargy and Stress Resistance at The Korea Society of Ginseng Spring Conference in 2022 held at Sejong University on the 21st. In particular, the timeliness of the results of this study are especially meaningful since an increasing number of people have complained of lingering fatigue and lethargy following recovery from coronavirus infection.

Key Points: 
  • - The Korea Society of Ginseng presented the results of a study on the effect of red ginseng on improving fatigue and lethargy.
  • SEOUL, South Korea, April 26, 2022 /PRNewswire/ --The Korea Society of Ginseng disclosed the results of a study titled The Effect of Red Ginseng on Improving Fatigue, Lethargy and Stress Resistance at The Korea Society of Ginseng Spring Conference in 2022 held at Sejong University on the 21st.
  • - According to Kim Kyung-chul, a family medicine specialist, red ginseng effectively reduces fatigue and stress.
  • The red ginseng group took 1000mg of red ginseng twice a day during the 16 weeks of chemotherapy.